COMP <GO>
RXRX vs DNLI // ENTERPRISE SCALE & MARKET CAP
Recursion Pharmaceuticals Inc. (NASDAQ) VS. Denali Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: RXRX 2
— DNLI 3
▲ ENTERPRISE SCALE & MARKET CAP LEADER: DNLI
LAST: $4.24 (-2.53%) • MKT CAP: $2.53B
market-cap
$2.53B
LAST: $19.32 (+0.16%) • MKT CAP: $3.09B
market-cap
$3.09B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RXRX VS. DNLI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RXRX | DNLI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 5.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -14.95% | -13.67% | -1.28 | DNLI | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 26.90% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.59 | 10.87 | -9.28 | DNLI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 2/9 | +2.00 | RXRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.1 | 45.3 | +10.82 | RXRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $2.53B | $3.09B | -$557.5M | DNLI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RXRX REV | DNLI REV | RXRX GROSS % | DNLI GROSS % | RXRX FCF | DNLI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $74.7M | $0 | 5.0% | — | -$378.3M | -$422.1M |
| FY 2024 | $58.8M | $0 | 23.1% | — | -$372.9M | -$363.6M |
| FY 2023 | $44.6M | $330.5M | — | — | -$289.8M | -$358.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RXRX // BETA 1.00
DNLI // BETA —